Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.
about
Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic ReviewNew models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication managementVelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsParathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort studyDynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.Emerging drugs for secondary hyperparathyroidism.A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoTreatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Regimen complexity and prescription adherence in dialysis patients.A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects.A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
P2860
Q26774337-8979ABDD-8A9D-4261-B032-756938740804Q33577423-20C6EF38-80AB-4DE0-9E5E-D3B74531EAF9Q34385273-9C29A74C-9CB0-4CB4-8AF7-5562A6C1DBB3Q35247578-A4A783C2-FE7B-468B-B0AF-6157988E3FFEQ35824855-3E5E727F-7C65-4DBE-A0E6-0B63D8A70CDBQ38363615-2398797E-7043-45B8-BD63-C59D3E69DE45Q39037214-50356FD5-FB7A-4E15-9053-57EF92C3A970Q39374348-252F5D70-0D77-4DEE-A1DC-B7D9C7BA0BE4Q44687612-F2CE1146-A085-4DF7-A65B-94D6953CA95FQ45755152-3BF12E98-5CEF-4C90-8960-42510565E912Q47102093-DB0BA276-36D5-4B58-984E-62B5E4AC0E5BQ52722043-1CF78838-B579-4BC0-818A-AAC08874E5ECQ55413395-59FCCFA0-D422-4C77-A712-9E93C210419B
P2860
Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Assessment of adherence to cin ...... ates in hemodialysis patients.
@en
Assessment of adherence to cin ...... ates in hemodialysis patients.
@nl
type
label
Assessment of adherence to cin ...... ates in hemodialysis patients.
@en
Assessment of adherence to cin ...... ates in hemodialysis patients.
@nl
prefLabel
Assessment of adherence to cin ...... ates in hemodialysis patients.
@en
Assessment of adherence to cin ...... ates in hemodialysis patients.
@nl
P2093
P1476
Assessment of adherence to cin ...... ates in hemodialysis patients.
@en
P2093
Charles McKee
Daniel W Coyne
Kirsten Moloney
Yekaterina Gincherman
P356
10.1111/J.1542-4758.2009.00397.X
P577
2009-08-28T00:00:00Z